Changes

89 bytes removed ,  12:35, 28 July 2018
Line 25: Line 25:  
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_inv(16)(p13.1q22)_or_t(16;16)(p13.1;q22);_CBFB-MYH11 Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]'''
 
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_inv(16)(p13.1q22)_or_t(16;16)(p13.1;q22);_CBFB-MYH11 Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]'''
   −
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
+
* Approximately 5-8% of AML cases have inv(16)(p13.1q22) or t(16;16)(p13.1;q22) [1,3].  Either rearrangement leads to a CBFB-MYH11 fusion gene and may be an early event in the development of Acute Myeloid Leukemia (AML) [2].
 
  −
Approximately 5-8% of AML cases have inv(16)(p13.1q22) or t(16;16)(p13.1;q22) [1, 3].  The translocation inv(16)(p13.1q22) or t(16;16)(p13.1;q22) leading to a CBFB-MYH11 fusion gene may be an early event in the development of Acute Myeloid Leukemia (AML) [2].
      
==Gene Overview==
 
==Gene Overview==